Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Shareholder Participation

LOS ANGELES, CA / ACCESSWIRE / October 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Help The Schall Law Firm Look Into Whether Zoetis Inc. Violated Securities Laws

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.432 per share for the fourth quarter of 2024. The dividend will be paid on Tuesday, December 3, 2024, to all holders of record of the Company's common stock as of the close of business on Thursday, October 31, 2024. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Afte.

Zoetis Declares Fourth Quarter 2024 Dividend

LOS ANGELES, CA / ACCESSWIRE / October 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Shareholder Participation In An Investigation Into Zoetis Inc For Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc. Is Being Inquired Into For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm

Zoetis excels in innovation, creating new categories and consistently raising the standard of care, outperforming competitors with strong execution. Disciplined capital allocation is evident with strategic exits and reinvestments in high-return growth areas, ensuring sustained business growth. Their market leadership, potential growth opportunities, and dividend metrics make ZTS a suitable candidate for the young dividend growth investor.

Zoetis: A Solid Choice For The Young Dividend Growth Investor

LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc. Is Being Looked Into For Securities Law Violations And Investors Are Encouraged To Reach Out To The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges Shareholders To Help Investigate Whether Zoetis Inc Committed Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Related Infractions

LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Encourages Impacted Shareholders To Reach Out

Accenture Plc

Amphenol

Domino's Pizza

Elevance Health Inc

Global Payments

Intuit

Mastercard

MSCI

Nordson

NXP Semiconductors

Old Dominion Freight Line

ResMed

Rollins

SPDR S&P 500 ETF Trust

Visa

Vanguard Dividend Appreciation ETF

The SPDR S&P 500 ETF Trust posted a gain of 2.10% in September as it continues marching on in 2024. The Top 15 dividend growth stocks for October 2024 offer an average dividend yield of 1.05% and appear to be about 20% undervalued based on dividend yield theory.

My Top 15 High Growth Dividend Stocks For October 2024

LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Urged To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Securities Related Infractions

LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Encourages Shareholder Participation

LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Invited To Help The Schall Law Firm Look Into Whether Zoetis Inc. Violated Securities Laws

LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Wants Shareholders To Contribute To A Securities Fraud Investigation Into Zoetis Inc

LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Join The Schall Law Firm's Inquiry Into Zoetis Inc. For Violating Securities Laws

LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Wants Shareholders With Losses To Lend A Hand

LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Whether Zoetis Inc. Violated Securities Laws And Affected Investors Should Reach Out

Carnival

Pfizer

Teledyne Technologies

Four S&P 500 laggards of this year have double-digit upside left for the rest of 2024. These are: CCL, PFE, ZTS, TDY.

Buy These 4 S&P 500 Year-to-Date Laggards With Solid Near-Term Upside

Zoetis, a leader in veterinary healthcare, has consistently outperformed the market with robust revenue growth and strong margins, even during industry challenges. The company's innovation, focus on companion animals, and strategic divestitures position it well for continued growth, despite prior concerns over drug risks. With a modest dividend yield, Zoetis remains a solid investment for dividend growth, backed by a $6 billion buyback program and long-term market potential.

Zoetis: Investing In Pet Health And Portfolio Wealth

LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Urged To Join The Schall Law Firm's Inquiry Into Zoetis Inc For Securities Fraud

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis and Danone recently announced a joint business development plan to drive sustainable practices on today's dairy farms through the power of genetics for healthier cows. Combining Danone's commitment to environmental stewardship with Zoetis' expertise in animal genetics, the partnership aims to innovate the dairy industry's approach to breeding for sustainability. The plan between the two companies is intended to enable Danone to leverage Zoetis' cutting-.

Zoetis and Danone Announce Strategic Partnership to Pioneer Sustainable Innovation in Dairy Farming Using the Power of Genetics

LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Zoetis Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Wants Impacted Investors To Reach Out

Comcast

Vici Properties

Optimism is growing as inflation eases and rate cuts drive the market. However, uncertainties remain, making selective, high-quality stock picks crucial. Despite high valuations, focusing on dividend stocks with strong fundamentals offers long-term growth and income potential in this evolving environment. I highlight three stocks that balance income, growth, and value, each positioned to outperform in a market fueled by economic shifts and favorable conditions.

3 Top Dividend Stocks Poised To Outshine In A Fed-Cutting Frenzy

LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Zoetis Stock (ZTS)